Suanfarma sells Halotech to ST Technologies
Suanfarma has exited biotechnology company Halotech DNA via a trade sale to Sexing Technologies, a business that specialises in the gender identification of beef-cattle semen.
Halotech has developed and commercialised in vitro diagnostic kits to assess DNA fragmentation in human and animal sperm cells.
Based in the Madrid Science Park, it was created by Suan Biotech in collaboration with Autonomous University of Madrid spin-off Chromacell.
The unquote" team is currently researching this transaction. In-depth deal information for subscribers will follow shortly.
If you have any information regarding this transaction, please contact Susannah Birkwood on +44 20 7004 7524 or susannah.birkwood@incisivemedia.com
Latest News
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Czech Republic-headquartered family office is targeting DACH and CEE region deals
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Ex-Rocket Internet leader Bettina Curtze joins Swiss VC firm as partner and CFO
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Estonia-registered VC could bolster LP base with fresh capital from funds-of-funds or pension funds








